Piper Sandler Upgrades Biogen to Overweight Following Apellis Acquisition

Apr 14, 2026 14:58 UTC

BIIB

Short term

Biogen shares climbed Tuesday after Piper Sandler raised its rating and price target. The upgrade follows the company's strategic move to acquire eye drug developer Apellis Pharmaceuticals.

Rating upgraded from Neutral to Overweight
Price target raised to $214 from $174
Strategic acquisition of Apellis Pharmaceuticals
Focus on expanding eye drug development pipeline
Positive immediate share price reaction

Biogen (BIIB) saw a positive market reaction on Tuesday following a rating upgrade from Piper Sandler, which shifted the biotech firm's outlook from Neutral to Overweight. The upgrade is primarily driven by Biogen's recent agreement to acquire Apellis Pharmaceuticals, a developer specializing in ocular treatments. This strategic acquisition is viewed as a key catalyst for the company's growth trajectory and expansion within the ophthalmology space. As part of the revision, Piper Sandler significantly increased its price target for BIIB, raising it to $214 from the previous $174. This adjustment reflects the analyst's confidence in the potential synergies and pipeline expansion resulting from the Apellis deal. The stock's upward movement reflects investor optimism regarding Biogen's ability to diversify its therapeutic portfolio and leverage Apellis's specialized drug development capabilities to drive future revenue.